A recent study by Hahn et al. (2014) indicated that PPARγ agonist rosiglitazone inhibited NPC cell growth by reducing the expression of ILK through activation of PPARγ- and AMPKα. The gene discussed is PPARG; the disease is nasopharyngeal carcinoma.